Abstract
Purpose:
A retrospective analysis was conducted to compare the tolerability and efficacy of single-agent capecitabine and 5-fluorouracil/leucovorin/irinotecan (FOLFIRI) in the first-line treatment of patients aged > or =65 years with metastatic colorectal cancer (mCRC).
Methods:
Consecutive patients with mCRC treated at the Military Medical Institute, Warsaw, between January 2003 and June 2008 were eligible. A total of 123 patients were identified (FOLFIRI, n = 67; capecitabine, n = 56).
Results:
The overall response rate with FOLFIRI was 28.1 versus 16.4% with capecitabine (P = 0.1398). Median time to disease progression with FOLFIRI was 8.8 versus 7.5 months with capecitabine (P = 0.20), and median overall survival was 19.0 versus 15.4 months (P = 0.93). In the FOLFIRI group, neutropenia and anaemia were significantly more frequent than in the capecitabine group. The main non-haematological toxicity was hand-foot syndrome found only in the capecitabine group.
Conclusion:
Single-agent capecitabine and FOLFIRI are effective first-line regimens in patients aged > or =65 years with mCRC.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Analysis of Variance
-
Anemia / chemically induced
-
Antimetabolites, Antineoplastic / adverse effects
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Capecitabine
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / pathology*
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / therapeutic use
-
Disease Progression
-
Feasibility Studies
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives*
-
Fluorouracil / therapeutic use
-
Humans
-
Irinotecan
-
Leucovorin / administration & dosage
-
Male
-
Neutropenia / chemically induced
-
Odds Ratio
-
Retrospective Studies
-
Survival Analysis
-
Treatment Outcome
Substances
-
Antimetabolites, Antineoplastic
-
Deoxycytidine
-
Capecitabine
-
Irinotecan
-
Leucovorin
-
Fluorouracil
-
Camptothecin